Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of sodium valproate during preparing medicament for treating retina disease

A technology for retinal diseases and sodium valproate, applied in drug combinations, cardiovascular system diseases, anhydride/acid/halide active ingredients, etc.

Inactive Publication Date: 2009-11-25
PEKING UNIV FIRST HOSPITAL
View PDF0 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Whether VPA can protect the optic nerve by inhibiting the apoptosis of photoreceptor cells has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sodium valproate during preparing medicament for treating retina disease
  • Application of sodium valproate during preparing medicament for treating retina disease
  • Application of sodium valproate during preparing medicament for treating retina disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0015] Example 1. Verification of the protective effect of sodium valproate on photoreceptor cells in mice with retinitis pigmentosa

[0016] 1. Materials and methods

[0017] 1. Research objects and groups

[0018] The experimental animals were retinal degeneration mice (Retinal Degeneration Mouse, rd mouse; purchased from Charles River Laboratories, USA), bred and bred by the Experimental Animal Center of Peking University First Hospital, and cycled with light (light for 12 hours, dark for 12 hours). 48 rd neonatal mice were selected and randomly divided into 8 groups, of which 4 were VPA groups and 4 were control groups, with 6 mice in each group, male or female.

[0019] 2. Administration method

[0020] The rd mice were weighed daily from birth to 28 days, and the drugs were injected daily according to the body weight. Wherein VPA group: VPA (Sigma company product, sodium valproate (Valproate Sodium, VPA)) is diluted to 10g / L (1%) with normal saline, every 1mL solution...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of sodium valproate during preparing medicament for treating retina disease, the treating of the retina disease is to protect the retina photoreceptor cell. It is proved that, the sodium valproate is applied to an animal model with pigmentary degeneration of retina which is one kind of the retina disease, the action for acting against the apoptosis of the photoreceptor cell, the progressive degrading of the photoreceptor cell can be delayed, the sodium valproate can be used as active component to prepare the retina disease neural protection medicament, especially to prepare the medicament for protecting the photoreceptor cell, and the good effect can be reached.

Description

technical field [0001] The invention relates to the application of sodium valproate in the preparation of medicines for treating retinal diseases. Background technique [0002] In many retinal diseases (eg, retinitis pigmentosa, age-related macular degeneration, etc.), loss of retinal photoreceptor cells can lead to irreversible vision loss. For such diseases, people have tried many methods to prevent the loss of retinal photoreceptor cells and repair retinal cell degeneration, including nutritional support therapy, gene therapy, and retinal cell transplantation. However, these methods have failed to achieve definite clinical efficacy. [0003] Among them, retinitis pigmentosa (RP) is a group of hereditary retinopathy characterized by degeneration of photoreceptor cells—cone and rod cells, and progressive impairment of pigment epithelial function. It is a very common cause of blindness in ophthalmology. disease. At present, the worldwide incidence rate is about 1 / 4000, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/19A61P9/10
Inventor 杨柳
Owner PEKING UNIV FIRST HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com